Search

Search Constraints

You searched for: Author/Creator Reuss, Alexander

Search Results

1. 2022-RA-1074-ESGO AGO-OVAR 2.29 (ENGOT-ov34): atezolizumab in combination with bevacizumab and chemotherapy vs bevacizumab and chemotherapy in recurrent ovarian cancer. (20th October 2022)

2. 2022-RA-276-ESGO Value of surgical cytoreduction for subsequent ovarian cancer relapse in patients previously treated with chemotherapy alone at 1st-relapse: a subanalysis of the DESKTOP III/ENGOT-ov20 trial. (20th October 2022)

3. 2022-RA-798-ESGO Diagnosis of first relapse and its impact on quality of life in patients with advanced ovarian cancer (AGO-OVAR 19/II). (20th October 2022)

6. Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future. Issue 1 (1st January 2016)

7. Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future. Issue 1 (January 2016)

8. Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: A metaanalysis of four prospective randomised phase III trials with 5114 patients. Issue 7 (May 2015)

9. Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer – a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34). Issue 12 (30th June 2020)